PT-141 (Bremelanotide) vs CJC-1295 & Ipamorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →CJC-1295 & Ipamorelin
The most popular growth hormone secretagogue combination. CJC-1295 (a GHRH analog) and Ipamorelin (a ghrelin mimetic) work synergistically to stimulate natural growth hormone release with potentially greater effects than either peptide alone.
Full details →Side-by-Side Comparison
| Aspect | PT-141 (Bremelanotide) | CJC-1295 & Ipamorelin |
|---|---|---|
| Mechanism | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. | CJC-1295 binds to GHRH receptors to sustain GH signaling and extend the half-life of growth hormone release. Ipamorelin triggers strong GH pulses by binding to ghrelin receptors. Together, they create both sustained and pulsatile GH release patterns that more closely mimic natural physiology. |
| Typical Dosage | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. | CJC-1295 (no DAC/Mod GRF 1-29): 100-300mcg combined with Ipamorelin 200-300mcg, administered 1-3 times daily. Best results when administered fasted or before sleep. |
| Administration | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. | Subcutaneous injection. Often administered before bedtime to enhance natural nighttime GH release, or in the morning fasted. The combination is typically pre-mixed or injected simultaneously. |
| Side Effects | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. | Water retention, tingling in extremities, mild headaches, lightheadedness, or increased hunger. Generally well-tolerated with minimal effect on cortisol or prolactin. |
| Best For |
What They Have in Common
Both PT-141 (Bremelanotide) and CJC-1295 & Ipamorelin are commonly used for: